Edition:
United States

C R Bard Inc (BCR.N)

BCR.N on New York Stock Exchange

318.63USD
22 Sep 2017
Change (% chg)

$1.26 (+0.40%)
Prev Close
$317.37
Open
$317.34
Day's High
$318.63
Day's Low
$317.34
Volume
37,167
Avg. Vol
158,471
52-wk High
$324.53
52-wk Low
$203.63

Latest Key Developments (Source: Significant Developments)

C. R. Bard receives FDA premarket approval of the Lutonix
Monday, 28 Aug 2017 09:00am EDT 

Aug 28 (Reuters) - C R Bard Inc -:C. R. Bard receives fda premarket approval of the lutonix® 035 drug coated balloon as the first and only DCB for the treatment of patients with dysfunctional av fistulae.C R Bard Inc- ‍lutonix® 035 drug coated balloon pta catheter is now available for sale in United States​.  Full Article

C.R. Bard shareholders approve proposed merger with Becton Dickinson
Tuesday, 8 Aug 2017 04:54pm EDT 

Aug 8 (Reuters) - Becton Dickinson And Co :Bard shareholders approve proposed merger with becton, dickinson.Becton dickinson and co - ‍proposed transaction is presently expected to close in fourth calendar quarter of 2017​.  Full Article

C R Bard receives civil investigative demand by DOJ in July
Friday, 28 Jul 2017 10:50am EDT 

July 28 (Reuters) - C R Bard Inc ::Says in July, separate civil investigative demand was served to company by DOJ.Says company is cooperating with Department of Justice's requests.DOJ demand seeks information on investigation into possible violations of False Claims Act.DOJ demand seeks information in connection with sales, marketing of Flochec, Quantaflo devices‍​.  Full Article

Becton Dickinson & Co and Bard get second requests from ftc under Hart-Scott-Rodino Act
Friday, 9 Jun 2017 05:15pm EDT 

June 9 (Reuters) - C R Bard Inc :Becton Dickinson and Co says co, Bard get second requests from ftc under Hart-Scott-Rodino act; cos continue to expect transaction to close in the fall of 2017‍​‍​.  Full Article

AngioDynamics lawsuit claims C.R. Bard is violating antitrust laws, harming competition, limiting access
Wednesday, 31 May 2017 06:00am EDT 

May 31 (Reuters) - AngioDynamics Inc ::AngioDynamics - "C.R. Bard has illegally tied sale of tip location systems to line of peripherally inserted central catheters," as per lawsuit filed by co.AngioDynamics - lawsuit claims that C.R. Bard will only sell proprietary stylet necessary to operate its tip location systems preloaded in its PICCs.  Full Article

Becton Dickinson, in connection with termination of merger, Bard must pay termination fee of $750 mln
Monday, 24 Apr 2017 07:47am EDT 

April 24 (Reuters) - Becton Dickinson and Co ::Becton Dickinson -in connection with termination of merger agreement under specified circumstances, Bard is required to pay co termination fee of $750 million.  Full Article

Becton Dickinson to buy Bard for $24 billion
Sunday, 23 Apr 2017 05:04pm EDT 

April 24 (Reuters) - C R Bard Inc :BD to acquire Bard for $24 billion.Deal immediately accretive and expected to generate high single-digit accretion to adjusted EPS in fiscal year 2019 to Becton Dickinson .BD will acquire Bard for $317.00 per bard common share in cash and stock.Agreement has been unanimously approved by boards of directors of both companies.Approximately $300 million of estimated annual, pre-tax, run-rate cost synergies are expected by fiscal year 2020 for Becton Dickinson .BD also expects to benefit from revenue synergies beginning in fiscal year 2019.Transaction is expected to improve BD's gross margins by approximately 300 basis points in fiscal year 2018.Deal expected to increase BD's earnings per share growth trajectory to mid-teens, and generate strong cash flow.Bd expects to contribute approximately $1.7 billion of available cash to fund transaction.BD also expects to fund deal with about $10 billion of new debt and about $4.5 billion of equity and equity linked securities.At deal closing, Bard shareholders will own approximately 15 percent of combined company.Bard shareholders will also receive $8 billion of BD common stock.  Full Article

C R Bard Q4 earnings per share $2.11
Thursday, 26 Jan 2017 04:15pm EST 

C R Bard Inc : Bard announces fourth quarter results . Q4 earnings per share $2.11 . Q4 sales $967.1 million versus I/B/E/S view $955.5 million . Q4 earnings per share view $2.74 -- Thomson Reuters I/B/E/S . Q4 adjusted earnings per share $2.77 . Sees FY 2017 sales up 4 to 5 percent . Sees FY 2017 adjusted earnings per share $11.45 to $11.75 . For full year 2017, net sales are forecasted to increase between 4 percent and 5 percent on an as-reported basis . FY2017 earnings per share view $11.40, revenue view $3.90 billion -- Thomson Reuters I/B/E/S . Excluding impact of foreign exchange, full year 2017 net sales are forecasted to increase between 6 percent and 6.5 percent .C R Bard-sees FY 2017 adjusted EPS to be between $11.45 and $11.75.  Full Article

Bard announces second quarter results
Tuesday, 26 Jul 2016 04:15pm EDT 

C R Bard Inc : Sees FY 2016 adjusted earnings per share $10.10 to $10.20 . Bard announces second quarter results . Q2 earnings per share $2.11 . Sees FY 2016 sales up 7 to 8 percent . Q2 sales $931.5 million versus i/b/e/s view $915.2 million . Q2 earnings per share view $2.47 -- Thomson Reuters I/B/E/S .FY2016 earnings per share view $10.15, revenue view $3.65 billion -- Thomson Reuters I/B/E/S.  Full Article

Bard announces $500 mln share repurchase authorization
Wednesday, 8 Jun 2016 04:15pm EDT 

C R Bard Inc: Bard announces $500 million share repurchase authorization .Buyback is in addition to approximately $205 million remaining under prior authorization announced in J2015.  Full Article

BRIEF-BD announces extension of exchange offers and consent solicitations for C. R. Bard Inc notes

* BD announces extension of exchange offers and consent solicitations for C. R. Bard Inc notes